Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAST HIKER: Ketamine vs ECT in TRD
NCT03272698Phase 4Recruiting
- Sponsor
- University of Saskatchewan
- Start
- Sep 2017
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by University of Saskatchewan. Primary endpoint: Number of treatments required to reach disease remission at 4 weeks. Started Sep 2017; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03272698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272698.